0000899243-23-002425.txt : 20230123 0000899243-23-002425.hdr.sgml : 20230123 20230123175437 ACCESSION NUMBER: 0000899243-23-002425 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220225 FILED AS OF DATE: 20230123 DATE AS OF CHANGE: 20230123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nokes Rachael CENTRAL INDEX KEY: 0001769138 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 23545415 MAIL ADDRESS: STREET 1: C/O SCPHARMACEUITCALS, INC. STREET 2: 2400 DISTRICT AVENUE CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: scPharmaceuticals Inc. CENTRAL INDEX KEY: 0001604950 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465184075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 617-517-0730 MAIL ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-25 0 0001604950 scPharmaceuticals Inc. SCPH 0001769138 Nokes Rachael C/O SCPHARMACEUTICALS INC. 2400 DISTRICT AVENUE, SUITE 310 BURLINGTON MA 01803 0 1 0 0 See Remarks Common Stock 2020-02-25 4 F 0 1981 10.09 D 11869 D Common Stock 2021-02-25 4 F 0 1976 7.27 D 9893 D Common Stock 2023-01-19 4 A 0 11700 6.14 A 21593 D Stock Option (right to buy) 6.14 2023-01-19 4 A 0 17550 0.00 A 2033-01-19 Common Stock 17550 17550 D The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. Consists of a restricted stock unit ("RSU") award made pursuant to the ScPharmaceuticals Inc. 2017 Stock Option and Incentive Plan. The RSUs vest as to 25% of the shares underlying the RSUs on each of the first four anniversaries of January 1, 2023, such that the RSUs will be fully vested on January 1, 2027. The option shares vest over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares will be fully vested on January 1, 2027. Chief Financial Officer and Treasurer /s/ Rachael Nokes 2023-01-23